tbuckley/cabot-search huggingface dataset:
Geriatrics in Medical Schools
Authors: Theodore R. Reiff, Ephraim Lisansky
Journal: Annals of Internal Medicine (1972)

Letters, Comments, and Corrections1 September 1972Geriatrics in Medical SchoolsTHEODORE R. REIFF, M.D., EPHRAIM LISANSKY, M.D., M.A.C.P.THEODORE R. REIFF, M.D.Search for more papers by this author, EPHRAIM LISANSKY, M.D., M.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-77-3-474 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: It is generally acknowledged that the medical care of older human beings in this country leaves much to be desired; the area of geriatric medicine is, to a large extent, a very neglected area of medical training. Actually, geriatric medicine provides an excellent environment for the in-depth study of human disease and for the training of physicians and allied medical personnel. At the present time the medical staffing of many of the geriatric hospitals in this country is quantitatively as well as qualitatively inadequate. This is not to say that there is not representation by competent and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1972Volume 77, Issue 3Page: 474-474KeywordsGeriatricsMedical staff Issue Published: 1 September 1972 PDF DownloadLoading ...
Living Donor Organ Transplantation
Authors: Ronald E. Domen
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improvement of Left Ventricular Dysfunction and of Survival Prognosis of Dilated Cardiomyopathy by Administration of Calcium Sensitizer SCH00013 in a Mouse Model
Authors: Takuro Arimura, Rika Sato, Noboru Machida, Hidenori Bando, Dong-Yun Zhan, Sachio Morimoto, Ryo Tanaka, Yoshihisa Yamane, Gisèle Bonne, Akinori Kimura
Journal: Journal of the American College of Cardiology (2010)
Article
Authors: Roger Ekins
Journal: Journal of the Royal Society of Medicine (2005)

In his review of Sylvia and James Tait's Quartet of Unlikely Discoveries Sir Richard Bayliss says, ‘In conjunction with Roger Ekins, the Taits developed immunoassay techniques for the measurement of thyroid hormones... ’. In their book they made no claim to have done so. In the early to mid 1950s the Taits were primarily engaged in work on hormones of the adrenal cortex, which culminated in their discovery of ‘electrocortin’ (aldosterone). I, on the other hand, working on radioisotope techniques for diagnosis and therapy, had reached the conclusion that radioisotopic tests of thyroid function could not be reliably interpreted without knowledge of the blood levels of thyroid hormone. Thus, albeit for differing reasons, both the Taits and I had an interest in measurement of hormones in blood. The technique they used for steroid hormones in many of their pioneering studies was the double-isotope labelled reagent method—too arduous and time-consuming for use in routine diagnosis. In 1954 I hit upon the concept I termed ‘saturation analysis’ (later generally known as ‘ligand’ or ‘binding’ assay), but 5 years were to pass before I had the opportunity to develop and publish a T4 binding assay employing radioiodinated thyroxine. The Taits moved to the Worcester Foundation in 1957. I do recall a conversation with James Tait (in the showers after a game of squash) in which I outlined the saturation analysis principle. He responded very encouragingly, but this was the entire extent of the Taits' participation in the development of binding assay techniques for the thyroid hormones.
APACHE-II score and Killip class for patients with acute myocardial infarction
Authors: Juan Mercado-Martínez, Ricardo Rivera-Fernández, Eduardo Aguilar-Alonso, Ángel García-Alcántara, Andrés Estivill-Torrull, Agustín Aranda-León, María Consuelo Guia-Rambla, Mari Paz Fuset-Cabanes
Journal: Intensive Care Medicine (2010)
Heads they win, tails we lose
Authors: C. Essex
Journal: BMJ (1995)

No doctor likes media stories about medical mishaps--the personal tragedy for the affected person; the initial reports quoting angry and upset relatives; the uneasy feeling that it could be you next time. But what really happened? What is the other side of the story? I was doing a general practitioner locum job. It keeps me humble being reminded of the difficulties that general practitioners face without the luxury of blood tests, x ray examinations, and, most importantly, nursing observation. I saw the child twice in 12 hours (at my request) and checked for signs of meningitis both times. I emphasised to the child's mother that she should contact me if she was worried. Evenso, that was not enough. Several hours later she rang to say the child was limp, so I arranged immediate admission. The child had H influenzae meningitis and was transferred to the intensive care unit at another hospital. I later spoke to the mother on the telephone to ask about the child's condition and said how sorry I was about his illness. I did not apologise for missing the diagnosis because I had looked for meningitis and he had no clinical signs of it when I saw him.

The next edition of the local weekly paper ran the front page banner, “Doctor misses meningitis,” with comments from the mother of “nearly killed my child” …
Alcohol intake worsens oxidative stress and piecemeal necrosis in patients with chronic hepatitis C
Authors: C. Rigamonti, E. Mottaran, E. Reale, F. Capelli, E. Maduli, R. Rolla, M. Vidali, R. Boldorini, M. Sartori, E. Albano
Journal: Journal of Hepatology (2003)
Involvement of Endogenous Endothelin-1 in Exercise-Induced Redistribution of Tissue Blood Flow
Authors: Seiji Maeda, Takashi Miyauchi, Motoyuki Iemitsu, Takumi Tanabe, Yoko Irukayama-Tomobe, Katsutoshi Goto, Iwao Yamaguchi, Mitsuo Matsuda
Journal: Circulation (2002)

Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor peptide. Exercise results in a significant redistribution of tissue blood flow, which greatly increases blood flow in active muscles but decreases it in the splanchnic circulation. We reported that exercise causes an increase of ET-1 production in the internal organ and then hypothesized that ET-1 participates in the exercise-induced redistribution of tissue blood flow. We investigated the effects of acute endothelin-A (ETA)-receptor blockade on regional tissue blood flow during exercise in rats.Regional blood flow in the kidney, spleen, stomach, intestine, and muscles was measured using the microsphere technique before and during treadmill running of 30 minutes duration at 30 m/min after pretreatment with either an ETA-receptor antagonist (TA-0201; 0.5 mg/kg) or vehicle in rats. Blood flow in the kidney, spleen, stomach, and intestine was decreased by exercise, but the magnitude of the decrease after pretreatment with TA-0201 was significantly smaller than that after pretreatment with vehicle. Furthermore, the increase in blood flow to active muscles induced by exercise was significantly smaller in rats pretreated with TA-0201 than those pretreated with vehicle.The present study revealed that ET-1-mediated vasoconstriction participates in the decrease of blood flow in the internal organs of rats during exercise, and therefore, that these actions of endogenous ET-1 partly contribute to the increase of blood flow in active muscles during exercise. The data suggest that endogenous ET-1 participates in the exercise-induced redistribution of tissue blood flow.
"Color Vectorcardiogram" Recorded with a Specially Designed Apparatus for Spatial Representation By Coloring
Authors: SHINJI KINOSHITA, TADASHI KOBAYASHI
Journal: Circulation (1971)

Using a vectorcardiogram only in the horizontal plane, spots of the vector loop were colored according to a specially designed apparatus, so that changes in height of the spots could be indicated by differences in those colors. Consequently, the spatial vectorcardiogram was represented by a single, colored graph, i.e. a "color vectorcardiogram." By the use of this graph, an attempt was made to facilitate the understanding of vectorcardiography for common clinicians. The colors corresponding to the heights of the deflections in the Y axis were chosen as follows: in a level of the origin or zero point of the vector loop, yellow; above the origin, reddish colors; and below the origin, bluish colors.
Letter from Chicago: Symposium
Authors: G. Dunea
Journal: BMJ (1990)

going to knock their socks off, let it creep up on them.Modesty and understatement is the best policy.Remember Watson and Crick and the double helix?"It has not escaped our notice that .." this is the most mind blowing discovery of the century.Use phrases like "it could beargued that .." and "one possible explanation is . .." you don't have to shout.The discussion is the most important part of the paper.People skip the methods and most of the results sections.Remember to criticise yourself first before anyone else gets the chance.After all in a couple of decades or centuries you may turn out to have been slightly wrong.Things like "some observer bias cannot be entirely excluded . .." and "it remains possible that some of the responses occurred by chance .." go down well with the sceptics but save yourself for "however" or "nevertheless . . .steps taken in the experiment render this highly unlikely" and "this would not explain the central finding," etc. Generallv keep it short and to the point.It is not a novel you are writing.If you get stuck, take a break.Leave the draft by your bedside.Sometimes a phrase just comes to you and its a shame to lose it. ConclusionWell, that is all the help you can get, from now on it is up to you.If it doesn't work out try not to get disheartened you will have made a contribution.Those hours or days spent listening to soothing music, daydreaming of Newton, Einstein, Darwin, and Freud have not gone to waste-you will have learnt what it means to write a classic paper.
MPs call for evidence on clinical trials and data disclosure
Authors: Z. Kmietowicz
Journal: BMJ (2012)

MPs have released details of the inquiry they are to hold early next year into clinical trials and the disclosure of data.

The Science and Technology Committee said that several events have sparked the need for the inquiry, including the publication of the book Bad Pharma by Ben Goldacre, which highlighted the fact that drug companies can choose which clinical trials of …
Contraindicated Medication Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention
Authors: Thomas T. Tsai
Journal: JAMA (2009)

The US Food and Drug Administration guides clinicians through drug labeling of medications that are contraindicated or not recommended for use in specific patient groups. Little is known about the use of such medications and their effects on outcomes in clinical practice.To investigate the use of the contraindicated/not-recommended agents enoxaparin and eptifibatide among dialysis patients undergoing percutaneous coronary intervention (PCI) and their association with outcomes.Data from 829 US hospitals on 22 778 dialysis patients who underwent PCI between January 1, 2004, and August 31, 2008.In-hospital bleeding and death.Five thousand eighty-four patients (22.3%) received a contraindicated antithrombotic; of these patients, 2375 (46.7%) received enoxaparin, 3261 (64.1%) received eptifibatide, and 552 (10.9%) received both. Compared with patients who did not receive a contraindicated antithrombotic, patients who did had higher rates of in-hospital bleeding (5.6% vs 2.9%; odds ratio [OR], 1.93; 95% confidence interval [CI],1.66-2.23) and death (6.5% vs 3.9%; OR, 1.68; 95% CI, 1.46-1.95). After multivariable adjustment, patients receiving contraindicated antithrombotics had significantly higher risks of in-hospital bleeding (OR, 1.66; 95% CI, 1.43-1.92) and death (OR, 1.24; 95% CI, 1.04-1.48). In 10 158 patients matched by propensity scores, receipt of contraindicated antithrombotics remained significantly associated with in-hospital bleeding (OR, 1.63; 95% CI, 1.35-1.98) but not in-hospital death (OR, 1.15; 95% CI, 0.97-1.36).In a sample of dialysis patients undergoing PCI, 22.3% received a contraindicated antithrombotic medication. In propensity-matched analysis, receipt of these medications was significantly associated with an increased risk of in-hospital major bleeding.
Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
Authors: James D. Joseph, Beatrice Darimont, Steven Govek, Dan Brigham, Jing Qian, John Sensintaffar, Gang Shao, Anna Aparicio, Mehmet Kahraman, Andiliy Lai, Kyoung-Jin Lee, Nhin Lu, Johnny Nagasawa, Michael Moon, Peter Rix, Nick Smith, Jeff Hager
Journal: Cancer Research (2014)

Abstract 80% of all breast cancers express the estrogen receptor alpha (ERα) and thus are treated with anti-hormonal therapies that directly block ER function (e.g.Tamoxifen) or hormone synthesis (Aromatase Inhibitors). While these therapies are initially effective, acquired resistance invariably emerges and disease progression ensues. Importantly, the majority of these tumors continue to depend on ERα for growth and survival via both ligand-dependent and ligand-independent pathways. The emerging evidence that ERα can be activated in the absence of estrogens via point mutations in ERα or cellular signaling pathways supports the development of agents that are not only competitive ERα antagonists but also reduce steady state levels of the receptor and thus limit both ligand dependent and independent signaling. We have identified two novel series of non-steroidal ERα antagonists, series I exemplified by ARN-810, now in clinical trials for treatment of endocrine resistant breast cancer, and series II, both of which induce degradation of ERα at picomolar concentrations resulting in significant reduction in steady state ERα protein levels in breast cancer cell lines. Using peptide-based conformational profiling, we show that both series induce ERα conformations that are distinct from both fulvestrant and tamoxifen indicating novel mechanism of action. In vitro, both ligand series are active on wild-type and the constitutively active ERα mutants found in endocrine resistant breast cancer patients. Importantly, these compounds yield tumor regression in both tamoxifen-sensitive and -resistant models of breast cancer in vivo. Based on their unique in vitro profile, and good pharmacokinetics following oral dosing, these compounds represent a novel class of Selective Estrogen Receptor Degraders (SERDs) that hold promise as a next generation therapy for the treatment of ER+ breast cancer as monotherapy, as well as in combination with agents that target other pathways involved in both intrinsic and acquired endocrine resistance. Citation Format: James D. Joseph, Beatrice Darimont, Steven Govek, Dan Brigham, Jing Qian, John Sensintaffar, Gang Shao, Anna Aparicio, Mehmet Kahraman, Andiliy Lai, Kyoung-Jin Lee, Nhin Lu, Johnny Nagasawa, Michael Moon, Peter Rix, Nick Smith, Jeff Hager. A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4757. doi:10.1158/1538-7445.AM2014-4757
Subungual Malignant Melanoma: Difficulty in Diagnosis
Authors: B. Leppard, K. V. Sanderson, F. Behan
Journal: BMJ (1974)

Subungual malignant melanoma developed on both great toes of a 61-year-old woman. The lesions had been diagnosed elsewhere as ingrowing toenails and had been treated as such for two years. The difficulty in clinical diagnosis is illustrated by the description of three other patients with subungual malignant melanoma. The tumour should be considered as a possible cause of any persistent abnormality of the nail bed or the nail itself, especially if it is pigmented.
The relationship between environmental exposures to phthalates and DNA damage in human sperm using the neutral comet assay.
Authors: Susan M Duty, Narendra P Singh, Manori J Silva, Dana B Barr, John W Brock, Louise Ryan, Robert F Herrick, David C Christiani, Russ Hauser
Journal: Environmental Health Perspectives (2003)

Phthalates are industrial chemicals widely used in many commercial applications. The general population is exposed to phthalates through consumer products as well as through diet and medical treatments. To determine whether environmental levels of phthalates are associated with altered DNA integrity in human sperm, we selected a population without identified sources of exposure to phthalates. One hundred sixty-eight subjects recruited from the Massachusetts General Hospital Andrology Laboratory provided a semen and a urine sample. Eight phthalate metabolites were measured in urine by using high-performance liquid chromatography and tandem mass spectrometry; data were corrected for urine dilution by adjusting for specific gravity. The neutral single-cell microgel electrophoresis assay (comet assay) was used to measure DNA integrity in sperm. VisComet image analysis software was used to measure comet extent, a measure of total comet length (micrometers); percent DNA in tail (tail%), a measure of the proportion of total DNA present in the comet tail; and tail distributed moment (TDM), an integrated measure of length and intensity (micrometers). For an interquartile range increase in specific gravity-adjusted monoethyl phthalate (MEP) level, the comet extent increased significantly by 3.6 micro m [95% confidence interval (95% CI), 0.74-6.47]; the TDM also increased 1.2 micro m (95% CI, -0.05 to 2.38) but was of borderline significance. Monobutyl, monobenzyl, monomethyl, and mono-2-ethylhexyl phthalates were not significantly associated with comet assay parameters. In conclusion, this study represents the first human data to demonstrate that urinary MEP, at environmental levels, is associated with increased DNA damage in sperm.
The association of latent Epstein?Barr virus infection with hydroa vacciniforme
Authors: None IWATSUKI, None XU, None TAKATA, None IGUCHI, None OHTSUKA, None AKIBA, None MITSUHASHI, None TAKENOSHITA, None SUGIUCHI, None TAGAMI, None KANEKO
Journal: British Journal of Dermatology (1999)

Patients with hydroa vacciniforme (HV)-like eruptions and malignant potential have been reported from Asia and Mexico, and those patients frequently had an associated latent Epstein–Barr virus (EBV) infection. In order to elucidate the association of latent EBV infection with HV, we studied six children with typical manifestations of HV by detection of EBV genes and EBV-related RNAs in biopsy specimens from cutaneous lesions. Cutaneous lesions of all six children with typical HV contained EBV-encoded small nuclear RNA (EBER)+ cells in 3–10% of the dermal infiltrates, whereas no Bam HI-H, l-fragment (BHLF) mRNA, or transcripts encoding EA-D antigen, were detected. No EBER + cells were detected in other inflammatory or benign lymphoproliferative skin disorders tested. Polymerase chain reaction amplification confirmed the presence of EBV DNA sequences in five of six biopsy specimens from the patients. Latent EBV infection is associated with the development of cutaneous lesions of HV.
Points: Associate specialist grade
Authors: J. A Tallack
Journal: BMJ (1984)

despite the evidence that in countries where health education of the public receives much higher priority than here, mortality from coronary heart disease has fallen below our own.The fall in mortality among doctors (and other professions) is almost certainly the result of the reduction of cigarette smoking and improved eating and exercise habits.This is what a population policy is likely to effect and is the responsibility of community physicians, health educators, and other health workers.The high risk strategy of detecting and advising those at greater risk whether from theirgenes or from their habits makes good sense and is already being carried out in several general practices.If Professor Oliver believes that this should be extended to the screening of the whole adult population to identify the 5%/, at highest risk he should spell out how this is to be done.Meanwhile it should be accepted that both strategies are necessary.
The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth <i>In vitro</i> and <i>In vivo</i>
Authors: Olivier E. Pardo, John Latigo, Rosemary E. Jeffery, Emma Nye, Richard Poulsom, Bradley Spencer-Dene, Nick R. Lemoine, Gordon W. Stamp, Eric O. Aboagye, Michael J. Seckl
Journal: Cancer Research (2009)

Abstract Lung cancer is the commonest cancer killer. Small cell lung cancer (SCLC) is initially chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of &amp;lt;5%. Consequently, novel therapies are urgently required and will likely arise from an improved understanding of the disease biology. Our previous work showed that fibroblast growth factor-2 induces proliferation and chemoresistance in SCLC cells. Here, we show that the selective fibroblast growth factor receptor (FGFR) inhibitor PD173074 blocks H-510 and H-69 SCLC proliferation and clonogenic growth in a dose-dependent fashion and prevents FGF-2–induced chemoresistance. These effects correlate with the inhibition of both FGFR1 and FGFR2 transphosphorylation. We then determined the efficacy of daily oral administration of PD173074 for 28 days in two human SCLC models. In the H-510 xenograft, tumor growth was impaired similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham–treated animals. Crucially, the effect of cisplatin was significantly potentiated by coadministration of PD173074. More dramatically, in H-69 xenografts, PD173074 induced complete responses lasting &amp;gt;6 months in 50% of mice. These effects were not a consequence of disrupted tumor vasculature but instead correlated with increased apoptosis (caspase 3 and cytokeratin 18 cleavage) in excised tumors. Moreover, in vivo imaging with 3′-deoxy-3′-[18F]fluorothymidine–positron emission tomography ([18F]FLT-PET) showed decreased intratumoral proliferation in live animals treated with the compound at 7 to 14 days. Our results suggest that clinical trials of FGFR inhibitors should be undertaken in patients with SCLC and that [18F]FLT-PET imaging could provide early in vivo evidence of response. [Cancer Res 2009;69(22):8645–51]